![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Sodium Acetate-generic Injection 4 mEq/mL is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
Lead Product(s): Sodium Acetate
Therapeutic Area: Nephrology Product Name: Sodium Acetate-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Woodward Pharma Services
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Microscopic and elemental analyses determined the presence of particulates in Maxivial (sodium acetate) injection that is composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Lead Product(s): Sodium Acetate
Therapeutic Area: Nephrology Product Name: Maxivial
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022